Aytu BioPharma, Inc. (NASDAQ:AYTU – Get Rating) – Equities research analysts at HC Wainwright lifted their FY2023 EPS estimates for shares of Aytu BioPharma in a report issued on Wednesday, November 16th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings per share of ($0.19) for the year, up from their prior forecast of ($0.44). The consensus estimate for Aytu BioPharma’s current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Aytu BioPharma’s FY2024 earnings at $0.01 EPS.
Aytu BioPharma (NASDAQ:AYTU – Get Rating) last posted its earnings results on Tuesday, September 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The company had revenue of $27.45 million for the quarter, compared to analyst estimates of $25.70 million. Aytu BioPharma had a negative return on equity of 47.20% and a negative net margin of 83.18%.
Aytu BioPharma Stock Performance
Institutional Trading of Aytu BioPharma
A number of hedge funds have recently modified their holdings of AYTU. Renaissance Technologies LLC lifted its stake in shares of Aytu BioPharma by 65.5% during the 3rd quarter. Renaissance Technologies LLC now owns 1,747,520 shares of the company’s stock worth $323,000 after buying an additional 691,738 shares during the last quarter. Prudential Financial Inc. lifted its stake in shares of Aytu BioPharma by 257.2% during the 3rd quarter. Prudential Financial Inc. now owns 145,550 shares of the company’s stock worth $27,000 after buying an additional 104,800 shares during the last quarter. Finally, Commonwealth Equity Services LLC raised its stake in Aytu BioPharma by 91.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 209,558 shares of the company’s stock worth $38,000 after purchasing an additional 99,859 shares in the last quarter. Institutional investors and hedge funds own 18.05% of the company’s stock.
About Aytu BioPharma
Aytu Biopharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old.
- Get a free copy of the StockNews.com research report on Aytu BioPharma (AYTU)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.